ARTICLE | Clinical News
Vigil vaccine: Phase III started
March 23, 2015 7:00 AM UTC
Gradalis began a double-blind, placebo-controlled, U.S. Phase III trial to evaluate intradermal Vigil vaccine given once monthly for 4-12 months in about 440 women who have been treated with primary c...